Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Core Insights - Neurocrine Biosciences, Inc. will participate in the Stifel 2025 Virtual CNS Forum on March 18, 2025, at 1:30 p.m. Eastern Time, with presentations from CEO Kyle Gano and CMO Eiry Roberts [1] - The live webcast of the event will be available on the company's website, with a replay accessible approximately one hour after the event and archived for about one month [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, Huntington's disease-related chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, along with a robust pipeline of compounds in mid- to late-phase clinical development [3] - With three decades of experience, Neurocrine applies insights into neuroscience to address complex conditions and aims to relieve suffering for patients with significant unmet needs [3]